Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Genotoxic anticancer drugs induce DNA damage, activating the DNA Damage Response (DDR) network.
• Ataxia Telangiectasia Mutated (ATM) protein is a key regulator of DDR, controlling cell cycle arrest, DNA repair, and apoptosis.
• ATM is a significant target for enhancing tumor radio- and chemosensitization.

Purpose of the Study:

• To review ATM inhibitors developed for cancer therapy.
• To discuss recent findings on the antineoplastic potential of ATM inhibitors.

Main Methods:

• Literature review of preclinical studies on ATM inhibitors.
• Analysis of small molecules developed to inhibit ATM specificity.
• Evaluation of ATM inhibitors' efficacy alone and in combination therapies.

Main Results:

• Development of specific small molecule ATM inhibitors by pharmaceutical industries and research labs.
• Preclinical evidence suggests ATM inhibitors can improve therapeutic outcomes.
• ATM inhibitors demonstrate potential in enhancing cancer treatment efficacy.

Conclusions:

• ATM inhibitors are a promising therapeutic strategy in oncology.
• Further research into ATM inhibitors may lead to improved cancer treatment protocols.
• Targeting ATM offers a viable approach for overcoming resistance and enhancing existing cancer therapies.